Potentials. Risks. Forecasts. Recommendations.
ZopaAI places value on your products and customers, by connecting your internal data to intelligence from more than 230,000+ external sources. Your teams see where measurable customer and product potential sits and the reasoning behind every recommendation.
- Market Data
- Trade Data
- Tenders
- News
- CRM-Systems
- ERP-Systems
- Customer Reports
- Procurement
Reliable custom solution for your industry
Pharma & Healthcare
Pharmacy, doctor, clinic, buying groups and tenders in one solution.
FMCG
Listings, promotions, stores, grocery chains, pricings, all in one AI.
Automotive
Supply chains, call-off behaviour and project business over long cycles.
Mechanical engineering
New machines, service and spare parts across the entire lifecycle.
Steel
Volume business, price volatility and margin risk per account.
Chemicals
Specialties, application engineering and tightly regulated markets.
Electrical engineering
Components, drives and switchgear sold through wholesale, panel builders and projects.
What works in Steel, does not work in FMCG. That is why ZopaAI provides custom solutions for each industry and adapts them to your individual needs and challenges.
Three steps towards your scientifically validated insights
ZopaAI adapts to your current tech stack. Minimal effort required from your side.
Connect
ERP, CRM, quotes and sell-out connected as they are. No migration.
Enrich
230,000+ external sources added and refreshed, not bought once.
Validate & Decide
Validate
Every output cross-checked against the metadata of 30,000+ scientific publications. Enabling evidence-based, hallucination-free outputs.
Decide
Potential and risk at every level, with the next best action and its source.
- 30,000+
- publications, their metadata checked against every claim
- Withheld
- when the source will not support it
Four levels, one figure
Every level is the same measurement, aggregated — not a separate number
Potentials, risks, forecasts and recommendations per customer.
Top 5 of 1,240 accounts
High order frequency, consistent basket growth, strong category alignment with growth segments.
Steady volume with seasonal uplift; new product lines gaining traction across two categories.
Order frequency down 12 % last quarter; catchment growth partially offsetting. Review recommended.
Order frequency −18 % over two quarters; competitor presence increasing in core categories.
Three consecutive quarters of volume decline; substitution risk in snacks elevated.
Distribution, substitution and lifecycle per product.
Top 4 of 86 product lines
New SKU launches driving velocity; distribution expanding into Eastern territory. Repeat rate +9 % QoQ.
Volume stable; margin pressure from private-label competition in core SKUs warrants active monitoring.
Three SKUs flagged as substitutable in buyer review; active category management required to retain shelf.
Strong digital shelf performance; promotional efficiency above category average. Watch competitor response.
Who is gaining, who is losing, and in which category.
Top 4 of 11 segments
Losing share to two regional entrants; price gap widened 6 % in last repricing cycle. Pricing response needed.
Marginal decline driven by promotional frequency gap; no structural threat identified at this stage.
Gained share following competitor SKU discontinuation; hold position with disciplined pricing.
Strong NPD pipeline resonating; distribution gains in convenience channel adding 0.8 pp.
Portfolio, regions, opportunities and risks. One number the board can act on.
All 4 regions
Top performer; three key accounts with above-average loyalty scores and growing basket sizes.
Stable growth; logistics improvements reduced out-of-stock rate by 4 % in Q3, supporting shelf presence.
Mixed results; two accounts in restructuring offset gains in pharma channel. Recovery expected Q2.
Lowest score; high competitor penetration and limited distribution coverage in rural sub-regions.
Potentials, risks, forecasts and recommendations per customer.
Top 5 of 1,240 accounts
High order frequency, consistent basket growth, strong category alignment with growth segments.
Steady volume with seasonal uplift; new product lines gaining traction across two categories.
Order frequency down 12 % last quarter; catchment growth partially offsetting. Review recommended.
Order frequency −18 % over two quarters; competitor presence increasing in core categories.
Three consecutive quarters of volume decline; substitution risk in snacks elevated.
Top 4 of 86 product lines
New SKU launches driving velocity; distribution expanding into Eastern territory. Repeat rate +9 % QoQ.
Volume stable; margin pressure from private-label competition in core SKUs warrants active monitoring.
Three SKUs flagged as substitutable in buyer review; active category management required to retain shelf.
Strong digital shelf performance; promotional efficiency above category average. Watch competitor response.
Top 4 of 11 segments
Losing share to two regional entrants; price gap widened 6 % in last repricing cycle. Pricing response needed.
Marginal decline driven by promotional frequency gap; no structural threat identified at this stage.
Gained share following competitor SKU discontinuation; hold position with disciplined pricing.
Strong NPD pipeline resonating; distribution gains in convenience channel adding 0.8 pp.
All 4 regions
Top performer; three key accounts with above-average loyalty scores and growing basket sizes.
Stable growth; logistics improvements reduced out-of-stock rate by 4 % in Q3, supporting shelf presence.
Mixed results; two accounts in restructuring offset gains in pharma channel. Recovery expected Q2.
Lowest score; high competitor penetration and limited distribution coverage in rural sub-regions.
ZOPA is the zone of possible agreement.
Every negotiation has a floor the seller will not go below and a ceiling the buyer will not go above. The range between them is where a deal is still possible, and it is usually guessed at. ZopaAI works it out from evidence: what the market pays, what this account has paid, what the alternatives cost, what the tender window allows.
The company is named after it because finding that range is the whole job.
Hallucination-free by procedure, not by promise.
Every statement is traceable to its inputs. If it is not supported by evidence, we withhold it.
An example of what your team sees: a validated answer and every source behind it.
EvidencedSeven accounts show rising order frequency against flat category growth. Two of them show early substitution risk.
Order history and quote log, last 24 months
Federal tender registry, hospital structure data
Peer-reviewed work on tender timing and supplier switching
Expected order value per account for Q4
Modelled internally, but no admissible source supports it at account level, so it is not returned.
Illustrative wording. Figures and names are not from a real client project.
Eight modules, one steering system
- 01Contact and visit steering
- 02Competitor analysis
- 03New customer search
- 04Customer scoring and prioritisation
- 05Forecasting
- 06Immediate action advice
- 07Cross-sell and upsell
- 08Pricing & negotiation
Voices About Us
PressZopaAI stands for reliable, scientifically verified AI for use in companies, free from AI hallucinations.
Who is behind ZopaAI
From research with DFKI to customers in 10 industries, in our first year.
- June 2025
- Founded
- 7-digit
- Revenue in year 1
- 10
- Industries served
Scientific AI, built by the people that master it.
Founded by a group of researchers, sales experts and economists, with strong ties to DFKI and CISPA.
Frequently asked questions
Simple answers to not so simple questions.
Yes. ZopaAI is hallucination-free by procedure: every output is cross-checked against the metadata of 30,000+ scientific publications, and anything the evidence does not support is withheld. What reaches you comes with its source.
Choose your industry and time.We will tailor the demo to you.
Not another sales pitch, but an honest discussion focusing on your needs. 30 minutes, no sensitive data, no risk, no cost.
- Use cases from your industry
- Valuable discussion, honest assessment.
- Focused on discovering potentials.